707 results on '"Metzler, Markus"'
Search Results
2. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression
3. A high proportion of germline variants in pediatric chronic myeloid leukemia
4. Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
5. Hodgkin lymphoma: hypodense lesions in mediastinal masses
6. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
7. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
8. An artificial intelligence-assisted clinical framework to facilitate diagnostics and translational discovery in hematologic neoplasia
9. Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
10. Machine Learning–Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing
11. Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
12. Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
13. Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
14. Temporal evolution and differential patterns of cellular reconstitution after therapy for childhood cancers
15. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
16. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
17. Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response
18. Model-based simulation of maintenance therapy of childhood acute lymphoblastic leukemia
19. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding
20. Rare pediatric tumors in Germany – not as rare as expected: a study based on data from the Bavarian Cancer Registry and the German Childhood Cancer Registry
21. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
22. Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)
23. Mixture density networks for the indirect estimation of reference intervals
24. Impact of regional SARS-CoV-2 proceedings on changes in diagnoses of pediatric malignancies in Bavaria during the COVID-19 pandemic.
25. Side Effects and Sequelae of Treatment for Chronic Myeloid Leukemia in Childhood and Adolescence
26. Präzisionsonkologie und Phase-I/II-Netzwerke in der Kinderkrebsmedizin
27. Data mining of pediatric reference intervals
28. Human-Level Differentiation of Medulloblastoma from Pilocytic Astrocytoma: A Real-World Multicenter Pilot Study
29. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis
30. Detection of signature double‐negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function
31. Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
32. Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults
33. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations
34. Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group
35. Molekulare Tumortherapie: Phase-I/II-Netzwerkstruktur der Gesellschaft für Pädiatrische Onkologie und Hämatologie
36. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921
37. Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
38. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia:Results From the Phase I Part of Study ITCC054/COG AAML1921
39. Exploitable metabolic dependencies in MLL-ENL–induced leukemia
40. Supplementary Figure S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
41. Supplementary Data S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
42. Supplementary Table S5 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
43. Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
44. Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations—is the term “thyroblastoma” more appropriate?
45. Influence of Turkish origin on hematology reference intervals in the German population
46. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
47. Data mining of reference intervals for coagulation screening tests in adult patients
48. Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia
49. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA
50. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.